14Stephan R Targan
Summary for 2004 [at-glance overview of Stephan R Targan work for the selected year as suggested by data mining algorithms]
This is an Authoratory overview of author Stephan R Targan. According to available data, in 2004 Stephan R Targan published at least 14 articles. This work was completed in collaboration with several authors including Papadakis, Konstantinos A and Vasiliauskas, Eric A. Many other authors have collaborated with Stephan R Targan as well. At least 8 different grants are awarded to Stephan R Targan to support this work. All time total of the grant awards on file exceeds $31,221,340.
Stephan R Targan is a key opinion leader in the specific area of Inflammatory Bowel Diseases. This author's rank is 2 when compared to all other authors using the same keyword. Analysis of the article abstracts and the titles suggests that Stephan R Targan professional interests are focused around "inflammatory bowel disease", "cells nk cells" and "bowel disease ibd". These might also be referred to as "crohn disease", "bowel disease" or "inflammatory bowel". Statistical analysis shows that Stephan R Targan's writing is likely to contains terms "disease", "cells", "patients", "ifn-gamma", "expression" and "bowel".
The affiliation of Stephan R Targan is uncertain, but might be related to Cedars-Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA. Luckily, several email addresses are on file.
| ENFRESRU |   | make correctionleave commentask question |
Images [images we found on the Internet for Stephan R Targan]
Do you know Stephan R Targan who matches the profile above? Click the photo and let us know!Alternative names (1) [other authors with names similar to Stephan R Targan]
Year 2004 Charts [Stephan R Targan frequent coauthors and the most common unique vocabulary terms for the selected year]
Historical Performance Charts [graphical overview of Stephan R Targan publication and funding history for the range of years]
Emails (2) [email addresses extracted from Stephan R Targan affiliations]
hidden to prevent spam, click here to reveal
Stephan R Targan Coauthors (37) [all coauthors with the number of joint publications]
Other [context-specific ads]
Affiliations (9) [condensed summary of the Stephan R Targan affiliations, the leading number and the color conveys importance]
- 3Cedars-Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
3Department of Medicine, Division of Gastroenterology, Cedars-Sinai Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California CA 90048, USA.
2Inflammatory Bowel Disease Research Center, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
1Gastrointestinal Unit, University of Edinburgh Department of Medical Sciences, School of Clinical and Molecular Medicine, Western General Hospital, Edinburgh EH4 2XU, UK.
1Inflammatory Bowel Disease Center and Burns and Allen Research Institute, Los Angeles, CA 90048, USA.
1Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
1Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, California 90048, USA.
1Corixa Corp, Seattle, Washington, USA.
1Inflammatory Bowel Disease Center, Los Angeles, California, USA.
Key Opinion Leader In [Stephan R Targan is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]
- 2Inflammatory Bowel Diseases | 7Crohn Disease | 18Antigens, Bacterial | 39Colitis, Ulcerative | 47Severity of Illness Index | 56Intestinal Mucosa | 101Interferon-gamma | 109Tumor Necrosis Factor-alpha | 153Flow Cytometry
Keywords (32) [keywords assigned to Stephan R Targan articles by PubMed, the leading number and the color conveys importance]
- 14Humans | 8Crohn Disease | 8Adult | 7Female | 7Male | 6Inflammatory Bowel Diseases | 6Middle Aged | 5Severity of Illness Index | 5Aged | 4Adolescent | 4Antigens, Bacterial | 4Tumor Necrosis Factor-alpha | 3Interferon-gamma | 3Intestinal Mucosa | 3Colitis, Ulcerative | 3Flow Cytometry | 2Child | 2Antibodies, Antineutrophil Cytoplasmic | 2Superantigens | 2T-Lymphocytes | 2Cells, Cultured | 2Time Factors | 2Porins | 2Gene Expression Regulation | 2Saccharomyces cerevisiae | 2Intestine, Small | 2Follow-Up Studies | 2Nod2 Signaling Adaptor Protein | 2Retrospective Studies | 2Cohort Studies | 2Antigens, CD2 | 2Tumor Necrosis Factor Ligand Superfamily Member 15
Stephan R Targan Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Stephan R Targan might be a good expert witness on these terms]
- 46disease | 44cells | 42patients | 31ifn-gamma | 23expression | 21bowel | 19inflammatory | 18tl1a | 18crohn | 16ibd | 13study | 12production | 12associated | 11intestinal | 11mucosal | 11activation | 11human | 10cd4 | 10adalimumab | 10light | 10role | 10stat5 | 9cxcr3 | 9therapy | 8infliximab | 8lymphocytes | 8lamina | 8propria | 8antigens | 8il-18 | 8il-12 | 8results
- 17crohn disease | 16bowel disease | 16inflammatory bowel | 11ifn-gamma production | 8lamina propria | 8il-12 il-18 | 7nk cells | 6cd4 cells | 6peripheral blood | 5disease ibd | 5cells nk | 5nodular hyperplasia | 4mucosal inflammation | 4patients ibd | 4pilot study | 4bacterial antigens | 4ulcerative colitis | 4patients inflammatory | 4cxcr3 lymphocytes | 4important role | 3disease activity | 3infliximab-allergic patients | 3nod2 card15 | 3inhibitors patients | 3receptor cxcr3 | 3selective cyclooxygenase-2 | 3disease patients | 3propria cells | 3card15 genotype | 3hematoxylin eosin | 3stat5 site | 3electron microscopy
- 16inflammatory bowel disease | 5cells nk cells | 4bowel disease ibd | 4patients inflammatory bowel | 3lamina propria cells | 3nod2 card15 genotype | 3chemokine receptor cxcr3 | 3ifn-gamma production human | 3cxcr3 lymphocytes normal | 3receptor cxcr3 lymphocytes | 3inhibitors patients inflammatory | 2costimulator ifn-gamma mucosal | 2spectrum gastrointestinal toxicity | 2limits usefulness ppd | 2tl1a tnf-family member | 2clinical remission crohn | 2study adalimumab infliximab-allergic | 2cyclooxygenase-2 inhibitors patients | 2disease patients limits | 2ompc i2 predominant | 2gastrointestinal toxicity effect | 2activation ifn-gamma gene | 2bowel disease patients | 2cells may regulate | 2role stat5 cd2 | 2anergy inflammatory bowel | 2selective cyclooxygenase-2 inhibitors | 2high-level serum antibodies | 2member potent costimulator | 2stat5 cd2 activation | 2group patients ompc | 2budesonide plus metronidazole
Reader's Comments (0) [comments posted by readers of Stephan R Targan profile]
no comments yet
Funding (8) [selected NIH grants to Stephan R Targan and the award amounts for recent years]
- INFLAMMATORY BOWEL DISEASE: NK ACTIVITY IN GUT MUCOSA (TARGAN, STEPHAN - 1981)
Grant # Award Year Award Amount, USD award information is not available Total up to 2004 $NA - IMMUNOLOGY CORE (TARGAN, STEPHAN - 1985)
Grant # Award Year Award Amount, USD award information is not available Total up to 2004 $NA - MECHANISM OF THE NK LETHAL HIT IN PROGRAMMED TUMOR CELLS (TARGAN, STEPHAN - 1984)
Grant # Award Year Award Amount, USD award information is not available Total up to 2004 $NA - IBD: ROLE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES (TARGAN, STEPHAN - 1991)
Grant # Award Year Award Amount, USD 5R01DK043026-02 1992 $141,227 5R01DK043026-04 1993 $167,579 Total up to 2004 $308,806 - ROLE OF ACTIVATED T CELLS IN GUT INJURY (TARGAN, STEPHAN - 1991)
Grant # Award Year Award Amount, USD 5R01DK043211-03 1992 $178,692 5R01DK043211-04 1993 $185,842 5R01DK043211-05 1994 $193,275 2R01DK043211-06A1 1997 $224,612 5R01DK043211-07 1998 $231,352 5R01DK043211-08 1999 $238,293 5R01DK043211-09 2000 $245,442 2R01DK043211-10 2001 $306,000 5R01DK043211-11 2002 $306,000 5R01DK043211-12 2003 $306,000 5R01DK043211-13 2004 $306,000 Total up to 2004 $2,721,508 - IBD--GENETIC 7 IMMUNOPATHOLOGIC MECHANISMS (TARGAN, STEPHAN - 1992)
Grant # Award Year Award Amount, USD 1P01DK046763-01 1992 $691,620 3P01DK046763-01S1 1993 $35,050 3P01DK046763-02S1 1993 $71,004 5P01DK046763-02 1993 $715,123 3P01DK046763-02S2 1994 $70,261 3P01DK046763-03S1 1994 $72,475 5P01DK046763-03 1994 $737,002 2P01DK046763-04 1995 $912,085 5P01DK046763-05 1996 $864,501 5P01DK046763-06 1997 $904,128 5P01DK046763-07 1998 $968,042 5P01DK046763-08 1999 $1,006,765 2P01DK046763-09 2000 $1,169,460 5P01DK046763-10 2001 $1,204,536 5P01DK046763-11 2002 $1,240,674 3P01DK046763-12S1 2003 $64,740 5P01DK046763-12 2003 $1,277,896 5P01DK046763-13 2004 $1,316,231 Total up to 2004 $13,321,593 - TNF ALPHA AND CROHNS DISEASE MUCOSAL INFLAMMATION (TARGAN, STEPHAN - 1999)
Grant # Award Year Award Amount, USD 1R01DK056328-01 1999 $258,714 5R01DK056328-02 2000 $266,473 5R01DK056328-03 2001 $267,370 5R01DK056328-04 2002 $282,208 5R01DK056328-05 2003 $283,655 2R01DK056328-06 2004 $390,000 Total up to 2004 $1,748,420 - FLAGELLIN REACTIVITY AS A MARKER FOR A SUBTYPE OF CROHN (TARGAN, STEPHAN - 2005)
Grant # Award Year Award Amount, USD award information is not available Total up to 2004 $NA
Stephan R Targan Articles (14) [selected PubMed articles for the year 2004 with the links to a full text at PubMed]
Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. (2004) >>
Gastrointestinal Unit, University of Edinburgh Department of Medical Sciences, School of Clinical and Molecular Medicine, Western General Hospital, Edinburgh EH4 2XU, UK.
14Targan, Stephan R, , 3Arnott, Ian D R, 5Landers, Carol J, 6Satsangi, Jack, , 3Drummond, Hazel E.Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa. (2004) >>
Inflammatory Bowel Disease Center and Burns and Allen Research Institute, Los Angeles, CA 90048, USA.
8Papadakis, Konstantinos A, 4Zhu, Daocheng, 14Targan, Stephan R, , 2Fleshner, Phillip R, 2Landers, Carol, .Enhancer role of STAT5 in CD2 activation of IFN-gamma gene expression. (2004) >>
Inflammatory Bowel Disease Research Center, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
14Targan, Stephan R, 15Young, Howard A, , , .Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. (2004) >>
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
28Martin, Paul, 1Tran, Tram, 14Targan, Stephan R, 7Vasiliauskas, Eric A, 3Cohen, Arthur H, 6Poordad, F Fred, 8Abreu, Maria T, 5Dubinsky, Marla C, 4Geller, Stephen A, 3Vierling, John M.High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. (2004) >>
Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, California 90048, USA.
, 6Greenberg, Gordon R, 7Feagan, Brian G, 4Steinhart, A Hillary, 14Targan, Stephan R, , 5Landers, Carol J, 3Seidman, Ernest.Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. (2004) >>
Cedars-Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA.
9Wei, Ping, 4Luo, Xia, 14Targan, Stephan R, , 5Landers, Carol J, , .LIGHT expression by mucosal T cells may regulate IFN-gamma expression in the intestine. (2004) >>
Cedars-Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
14Targan, Stephan R, 5Ware, Carl F, , , .The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. (2004) >>
Department of Medicine, Division of Gastroenterology, Cedars-Sinai Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
, 8Papadakis, Konstantinos A, 14Targan, Stephan R, 7Vasiliauskas, Eric A, 8Abreu, Maria T, .A pilot study of adalimumab in infliximab-allergic patients. (2004) >>
Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA.
, 14Targan, Stephan R, 8Abreu, Maria T, , , 8Papadakis, Konstantinos A, 4Smith, Katie, , , , 7Vasiliauskas, Eric A, 4Lechago, Juan, 5Dubinsky, Marla C, 1Ippoliti, Andrew.TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. (2004) >>
Cedars-Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA.
9Wei, Ping, , 8Papadakis, Konstantinos A, 4Luo, Xia, 14Targan, Stephan R, 2Landers, Carol, , .Bacterial flagellin is a dominant antigen in Crohn disease. (2004) >>
Corixa Corp, Seattle, Washington, USA.
3Cong, Yingzi, 2Hershberg, Robert M, , 8Elson, Charles O, 14Targan, Stephan R, 2Lodes, Michael J, , 5Landers, Carol J.High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. (2004) >>
Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
, 8Papadakis, Konstantinos A, , 14Targan, Stephan R, 7Vasiliauskas, Eric A, .Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. (2004) >>
Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
, 8Papadakis, Konstantinos A, 10Yang, Huiying, 14Targan, Stephan R, 7Vasiliauskas, Eric A, 1Lin, Ying-Chao, 2Fleshner, Phillip R, 3Taylor, Kent D, 11Rotter, Jerome I, , 5Landers, Carol J.Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. (2004) >>
Inflammatory Bowel Disease Center, Los Angeles, California, USA.
, 8Papadakis, Konstantinos A, 14Targan, Stephan R, 7Vasiliauskas, Eric A, , 5Dubinsky, Marla C, 4Lo, Simon K, .
Science Trivia (2) [Interactive math & science trivia questions]
The content of this page was generated automatically by a computer program.
Copyright © 2006-2010 Authoratory.com | All rights reserved | Terms of use | Privacy policy